Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;39(8):2030-2034.
doi: 10.1038/s41375-025-02648-w. Epub 2025 Jun 24.

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes

Clifford M Csizmar  1 , Anuya Natu  1 , Mark Gurney  1 , Saubia Fathima  1 , Ali Khalid A Alsugair  1 , Rashmi Kanagal-Shamanna  2 , Sanam Loghavi  2 , Alexandre Bazinet  3 , Kelly Chien  3 , Danielle Hammond  3 , Courtney DiNardo  3 , Tapan Kadia  3 , Farhad Ravandi-Kashani  3 , Naveen Pemmaraju  3 , Koji Sasaki  3 , Terra L Lasho  1 , Christy M Finke  1 , Aref Al-Kali  1 , Hassan Alkhateeb  1 , Kebede Begna  1 , Naseema Gangat  1 , Mehrdad Hefazi Torghabeh  1 , Aasiya Matin  1 , Abhishek A Mangaonkar  1 , Antoine N Saliba  1 , Ayalew Tefferi  1 , Guillermo Garcia-Manero  3 , Hagop M Kantarjian  3 , Rami S Komrokji  4 , Zhuoer Xie  4 , Najla A Ali  4 , David Sallman  4 , Eric Padron #  4 , Guillermo Montalban-Bravo #  3 , Mrinal M Patnaik #  5
Affiliations

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes

Clifford M Csizmar et al. Leukemia. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: MMP has received research funding from Kura Oncology, Stem Line, Epigenetix, Polaris and has served on the advisory board for CTI pharmaceuticals. Ethics approval: This retrospective study was approved by the Institutional Review Boards (IRB) at each center. The IRBs deemed this study to be minimal risk and thus exempt from written informed consent.

References

    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. - PubMed - PMC
    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. - PubMed - PMC
    1. Marando L, Csizmar CM, Patnaik MM. Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica 2025;110:22–36.
    1. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34:1407–21. - PubMed
    1. Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, et al. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024;109:3419–25. - PubMed - PMC

LinkOut - more resources